Merestinib
As of the edition of 20 October 2026, Merestinib is a small molecule: stopped in 2023; acts on MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Immune system; Skin and connective tissue; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 2 | 0 | 1 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2009 to now |